ME02640B - Farmaceutske formulacije 514 - Google Patents

Farmaceutske formulacije 514

Info

Publication number
ME02640B
ME02640B MEP-2016-204A MEP20416A ME02640B ME 02640 B ME02640 B ME 02640B ME P20416 A MEP20416 A ME P20416A ME 02640 B ME02640 B ME 02640B
Authority
ME
Montenegro
Prior art keywords
formulation
active agent
matrix polymer
weight
copovidone
Prior art date
Application number
MEP-2016-204A
Other languages
German (de)
English (en)
French (fr)
Inventor
Michael Karl Bechtold
Claudia Bettina Packhaeuser
Julie Kay Cahill
Katja Maren Fastnacht
Bernd Harald Liepold
Kieran James Lennon
Benedikt Steitz
Original Assignee
Kudos Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41396997&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME02640(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kudos Pharm Ltd filed Critical Kudos Pharm Ltd
Publication of ME02640B publication Critical patent/ME02640B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (27)

1. Farmaceutska formulacija koja obuhvata aktivni agens u cvrštoj disperziji sa matriksnim polimerom, naznačena time što aktivni agens je 4-[3-( 4-ciklopropankarbonii-piperazin-1-karbonii)-4-fluoro-benzii]-2H-ftaiazin-1-on ili so ili solvat od toga, te matriksni polimer pokazuje nisku higroskopnost i visoku temperaturu omeksavanja.
2. Formuiacija kako se zahteva u patentnom zahtevu 1, naznačena time što je aktivni agens u stabiinom amorfnom obliku.
3. Formulacija kako se zahteva u patentnom zahtevu 2, naznačena time što je harem 90% aktivnog agensa u amorfnom obliku.
4. Formuiacija kako se zahteva u patentnom zahtevu 2, naznačena time što je barem 95% aktivnog agensa u amorfnom obliku.
5. Formuiacija kako se zahteva u patentnom zahtevu 2, naznačena time što je 100% aktivnog agensa u amorfnom obliku.
6. Formuiacija kako se zahteva u biio kojem od patentnih zahteva 1 do 5, naznačena time što je matriksni polimer odabran izmedu: kopovidona, hidroksipropil metilceluloza ftalata (HPMCP), hidroksipropil metilceluloza acetat sukcinata (HPMCAS), 2-hidroksipropil -P-ciklodekstrina (HPBCD), hidroksipropil metilceluloze (hipromeloza, HPMC), polimetakrilata, hidroksipropil celuloze (HPC) i celuloza acetat ftalata (CAP).
7. Formulacija kako se zahteva u bilo kojem od patentnih zahteva 1 do 5, naznačena time što matriksni polimer je kopovidon.
8.Formulacija kako se zahteva u patentnom zahtevu 7, naznačena time što je kopovidon ko-polimer sa 1-vinil-2-pirolidonom i vinil acetatom u srazmeri od 6:4 maseno.
9. Formulacija kako se zahteva u bilo kojem od patentnih zahteva 1 do 8, naznačena time što je srazmera aktivni agens:matriksni polimer težinski od 1:0,25 do 1:10.
10. Formulacija kako se zahteva u patentnom zahtevu 9, naznačena time što je srazmera aktivni agens:matriksni polimer težinski 1 :2:2 do 1: 10.
11. Formulacija kako se zahteva u patentnom zahtevu 9, naznačena time što je srazmera aktivni agens:matriksni polimer težinski 1 :2 do 1 :4.
12. Formulacija kako se zahteva u bilo kojem od prethodnih patentnih zahteva naznačena time što je količina aktivnog agensa po jedinicnoj dozi harem 20% težinski.
13. Formulacija kako se zahteva u patentnom zahtevu 12 naznačena time što je količina aktivnog agensa po jedinicnoj dozi od 20% do 30% težinski.
14. Formulacija kako se zahteva u bilo kojem od prethodnih patentnih zahteva, naznačena time što čvrsta disperzija ukljucuje popvršinski aktivni agens ilili plastiftkator.
15. Formulacija kako se zahteva u patentnom zahtevu 14, naznačena time što je površinski aktivan agens odabran izmedu: natrijum dodecil sulfata (natrijum lauril sulfat); dokusat natrijuma; cetrimida; benzetonijum hlorida; cetilpiridinijum hlorida; laurinske kiseline; polioksietilen alkil etara; polioksietilen sorbitan masna kiselina estara, npr. polisorbata 20, 40, 60 i 80; polioksietilen ulje ricinusa derivata, npr. Cremophor RH40™; polioksietilen stearatea i poloksamera.
16. Formulacija kako se zahteva u bilo kojem od prethodnih patentnih zahteva naznačena time što je ukupna količina aktivnog agensa u formulaciji od 25 mg do 400 mg.
17. Formulacija kako se zahteva u patentnom zahtevu 1, naznačena time što je matriksni polimer kopovidon i formulacija nadalje obuhvata glidant, rastvorljivi punioc I lubrikant.
18. Formulacija kako se zahteva u patentnom zahtevu 17, naznačena time što je glidant silicijum dioksid, rastvorljivi punioc je manito! i lubrikant je natrijum stearil fumarat.
19. Formulacija kako se zahteva u patentnom zahtevu 1, naznačena time što je matriksni polimer kopovidon, srazmera aktivni agens:matriksni polimer težinski je 1:2.3 I ukupna količina aktivnog agensaje 25% težinski.
20. Formulacija kako se zahteva u patentnom zahtevu 19, naznačena time što formulacija takode obuhvata 1,8% težinski koloidnog silicijum dioksida, 14.7%% težinski manitola i 1% težinski natrijum stearil fumarata.
21. Formulacija kako se zahteva u bilo kojem od prethodnih patentnih zahteva, naznačena time što se čvrsta disperzija radi isparavanjem rastvaraca ili ekstruzijom raštopa.
22. Formulacija kako se zahteva u patentnom zahtevu 21, naznačena time što se čvrsta disperzija radi ekstruzijom raštopa.
23. Formulacija prema bilo kojem od prethodnih patentnih zahteva, naznačena time što je formulacija tableta za oralnu primenu.
24. Dnevna farmaceutska doza 4-[3-( 4-ciklopropankarbonil-piperazin-1-karbonil)-4 fluoro-benzil]-2H-ftalazin-1-ona za lecenje kancera kod pacijenta, naznačena time što doza obuhvata 10 do 1000 mg 4-[3-( 4-ciklopropankarbonil-piperazin-1-karbonil)-4-fluoro-benzil]-2H-ftalazin-1-ona u cvrštoj disperziji sa matriksnim polimerom koji pokazuje nisku higroskopnost i visoku temperaturu omeksavanja.
25. Dnevna farmaceutska doza kako se zahteva u patentnom zahtevu 24, naznačena time što je matriksni polimer kopovidon i srazmera 4-[3-(4-ciklopropankarbonil-piperazin-1-karbonil)-4-fluoro-benzil]-2H-ftalazin-1-ona naprema matriksnom polimeru težinski je 1:2 do 1:4.
26. Dnevna farmaceutska doza kako se zahteva u patentnim zahtevima 24 ili 25, naznačena time što se dnevna farmaceutska doza dostavi u manje od 4 jedinice po danu.
27. Postupak proizvodnje čvrste amorfne disperzije 4-[3-(4-ciklopropankarbonilpiperazin-1-karbonil)-4-fluoro-benzil]-2H-ftalazin-1-ona naznacen time što obuhvata: (i) mesanje podesne koliCine 4-[3-(4-ciklopropankarbonil-piperazin-1-karbonil)-4-fluoro-benzil]-2H-ftalazin-1-ona ili farmaceutski prihvatlj ive soli ili solvata od toga sa zeljenom kolicinom harem jednog matriksnog polimera, u cemu matriksni polimer pokazuje nisku higroskopnost i visoku temperaturu omeksavanja; (ii) povecanje temperature smese da se dobije raštop; i (ili) ekstrudiranje raštopa da se dobije cvrsti proizvod.
MEP-2016-204A 2008-10-07 2009-10-05 Farmaceutske formulacije 514 ME02640B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10334708P 2008-10-07 2008-10-07
PCT/GB2009/051309 WO2010041051A1 (en) 2008-10-07 2009-10-05 Pharmaceutical formulation 514
EP09740728.2A EP2346495B2 (en) 2008-10-07 2009-10-05 Pharmaceutical formulation 514

Publications (1)

Publication Number Publication Date
ME02640B true ME02640B (me) 2017-06-20

Family

ID=41396997

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2016-204A ME02640B (me) 2008-10-07 2009-10-05 Farmaceutske formulacije 514

Country Status (42)

Country Link
US (13) US8475842B2 (me)
EP (1) EP2346495B2 (me)
JP (1) JP5524220B2 (me)
KR (1) KR101668499B1 (me)
CN (1) CN102238945B (me)
AR (2) AR073792A1 (me)
AU (1) AU2009300866B2 (me)
BR (2) BR122021018683B1 (me)
CA (1) CA2737400C (me)
CL (1) CL2011000774A1 (me)
CO (1) CO6361906A2 (me)
CR (1) CR20110186A (me)
CU (1) CU24032B1 (me)
CY (2) CY1118190T1 (me)
DK (1) DK2346495T4 (me)
DO (1) DOP2011000094A (me)
EA (1) EA020783B1 (me)
EC (1) ECSP11010960A (me)
ES (1) ES2598178T5 (me)
FI (1) FI2346495T4 (me)
HN (1) HN2011000947A (me)
HR (1) HRP20161154T4 (me)
HU (2) HUE030800T2 (me)
IL (1) IL211809A (me)
LT (2) LT2346495T (me)
ME (1) ME02640B (me)
MX (1) MX2011003740A (me)
MY (1) MY160340A (me)
NI (1) NI201100070A (me)
NO (1) NO2018038I1 (me)
NZ (1) NZ592719A (me)
PE (1) PE20110893A1 (me)
PL (1) PL2346495T5 (me)
PT (1) PT2346495T (me)
RS (1) RS55157B2 (me)
SA (1) SA109300599B1 (me)
SI (1) SI2346495T2 (me)
TW (1) TWI461418B (me)
UA (1) UA106878C2 (me)
UY (1) UY32162A (me)
WO (1) WO2010041051A1 (me)
ZA (1) ZA201103333B (me)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2598178T5 (es) * 2008-10-07 2023-12-26 Kudos Pharm Ltd Formulación farmacéutica 514
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
TW201202234A (en) 2010-06-09 2012-01-16 Abbott Lab Solid dispersions containing kinase inhibitors
JP5823484B2 (ja) * 2010-07-14 2015-11-25 千寿製薬株式会社 α―ケトアミド誘導体固体分散体
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
CA3152557A1 (en) * 2010-10-29 2012-05-03 Abbvie Inc. Solid dispersions containing an apoptosis-inducing agent
PT2643322T (pt) 2010-11-23 2017-11-13 Abbvie Inc Sais e formas cristalinas de um agente indutor de apoptose
TWI620736B (zh) 2010-11-23 2018-04-11 艾伯維巴哈馬有限公司 使用選擇性ｂｃｌ-２抑制劑之治療方法
GB201103837D0 (en) * 2011-03-07 2011-04-20 Oxagen Ltd Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid
CN108542906A (zh) 2011-11-11 2018-09-18 诺华股份有限公司 治疗增生性疾病的方法
ES2695099T3 (es) 2011-11-23 2019-01-02 Array Biopharma Inc Formulaciones farmacéuticas
NL2009367C2 (en) * 2012-08-27 2014-03-03 Stichting Vu Vumc Microscopic imaging apparatus and method to detect a microscopic image.
PL2938598T3 (pl) 2012-12-31 2017-05-31 Cadila Healthcare Limited Podstawione pochodne ftalazyn-1 (2H)-onu jako selektywne inhibitory polimerazy-1 poli(ADP-rybozy)
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
AR101476A1 (es) 2014-08-07 2016-12-21 Acerta Pharma Bv Métodos para tratar cánceres, enfermedades inmunes y autoinmunes, y enfermedades inflamatorias en base a la tasa de ocupación de la tirosin quinasa de bruton (btk) y a la tasa de resíntesis de la tirosin quinasa de bruton (btk)
CN104434809B (zh) * 2014-12-10 2018-10-16 北京科莱博医药开发有限责任公司 一种奥拉帕尼固体分散体制剂及其制备方法
CN105777651A (zh) * 2015-01-13 2016-07-20 江苏豪森药业集团有限公司 聚腺苷酸二磷酸核糖转移酶抑制剂的晶型及其制备方法和医药用途
WO2016155655A1 (zh) 2015-04-03 2016-10-06 上海瑛派药业有限公司 Parp抑制剂固体药物剂型及其应用
CN106265580B (zh) * 2015-05-18 2020-09-08 中国科学院上海药物研究所 Somcl-9112固体分散体、其制备方法及包含其的somcl-9112固体制剂
CN112010809A (zh) * 2015-06-12 2020-12-01 苏州科睿思制药有限公司 奥拉帕尼的晶型i及其制备方法
US20170105937A1 (en) * 2015-10-16 2017-04-20 Cadila Healthcare Limited Olaparib co-precipitate and preparation method thereof
CN105254572A (zh) * 2015-11-09 2016-01-20 北京科莱博医药开发有限责任公司 一种奥拉帕尼的晶型及其制备方法和应用
ITUB20159206A1 (it) * 2015-12-22 2017-06-22 Olon Spa Forme cristalline e amorfe di olaparib
US20170204067A1 (en) 2016-01-14 2017-07-20 Scinopharm Taiwan, Ltd. Crystalline forms of olaparib and manufacturing processes therefor
CZ2016391A3 (cs) 2016-06-29 2018-01-10 Zentiva, K.S. Farmaceutická formulace olaparibu
CN108201536A (zh) 2016-12-16 2018-06-26 中国科学院上海药物研究所 一种奥拉帕尼口服缓控释药物组合物及其用途
CA3066441A1 (en) * 2017-06-12 2018-12-20 Protein Dynamic Solutions, Inc. Method and system for analysis of crystals and crystallization
WO2019133864A1 (en) 2017-12-29 2019-07-04 Accutar Biotechnology DUAL INHIBITORS OF PARP1 and CDK
CA3031777A1 (en) 2018-01-31 2019-07-31 Apotex Inc. Crystalline form of olaparib
CN109293576A (zh) * 2018-11-08 2019-02-01 威海贯标信息科技有限公司 一种小粒度奥拉帕尼的制备方法
JP7469304B2 (ja) * 2018-11-16 2024-04-16 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 Ｐａｒｐインヒビタを含む医薬組成物
TW202104228A (zh) * 2019-04-11 2021-02-01 美商必治妥美雅史谷比公司 用於達到治療血漿濃度之增加效能的非晶形固體及經溶解調配物
CN110013466B (zh) * 2019-05-28 2021-11-30 天津中医药大学 一种小檗红碱固体分散体粉末及制备方法及应用
US10703728B1 (en) 2019-06-18 2020-07-07 Scinopharm Taiwan, Ltd. Crystalline form of olaparib and a process for preparing the same
KR102512868B1 (ko) * 2019-12-20 2023-03-22 주식회사 삼양홀딩스 올라파립의 용해도 및 생체이용율이 개선된 조성물
WO2021133886A1 (en) 2019-12-23 2021-07-01 Accutar Biotechnology Combinations of estrogen receptor degraders and cyclin-dependent kinase inhibitors for treating cancer
CA3166741A1 (en) 2020-01-09 2021-07-15 Astrazeneca Ab Combination therapy for treating cancer
CN113288859B (zh) * 2020-02-21 2024-11-22 上海宣泰医药科技股份有限公司 奥拉帕尼药物组合物及其制剂、制备方法和用途
CN113350349B (zh) * 2020-03-04 2022-11-11 中国科学院上海药物研究所 奥拉帕尼溶出增强组合物
US12012386B2 (en) 2020-09-16 2024-06-18 Nuformix Technologies Limited Olaparib oxalic acid cocrystals and their pharmaceutical use
KR102707060B1 (ko) * 2020-12-01 2024-09-13 주식회사 삼양홀딩스 안정성 및 생체이용율이 개선된 올라파립 고체 분산체 조성물
CN112843007A (zh) * 2021-02-04 2021-05-28 石药集团中奇制药技术（石家庄）有限公司 一种奥拉帕利片
EP4312978A2 (en) 2021-03-27 2024-02-07 TRX Biosciences Limited Compositions having improved bioavailability of therapeutics
US20240269073A1 (en) * 2021-06-07 2024-08-15 Zerion Pharma ApS Co-amorphous forms for use in cancer therapy
US20240351989A1 (en) * 2021-08-09 2024-10-24 Glenmark Life Sciences Limited Process for the preparation of olaparib, and crystalline form thereof
WO2023084311A1 (en) 2021-11-10 2023-05-19 Nuformix Technologies Limited Olaparib hydroxybenzoic acid cocrystals and their pharmaceutical use
JP2025509680A (ja) * 2022-03-14 2025-04-11 ティーアールエックス バイオサイエンシズ リミテッド 治療薬のバイオアベイラビリティを改善した組成物およびその使用
TW202408509A (zh) * 2022-07-14 2024-03-01 大陸商西藏海思科製藥有限公司 雜芳基衍生物的藥物組合物及其在醫藥上的應用
CN115998699B (zh) * 2023-02-13 2025-06-24 中国药科大学 一种3d打印奥拉帕利片及其制备方法
CN117205169A (zh) * 2023-10-26 2023-12-12 宁夏医科大学 一种奥拉帕利片及其制备方法
WO2026013152A1 (en) 2024-07-09 2026-01-15 Stada Arzneimittel Ag Pharmaceutical composition comprising olaparib
US12383633B1 (en) 2024-10-01 2025-08-12 Zymeron Corporation Injectable formulations of PARP inhibitors and uses thereof

Family Cites Families (142)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2143745A1 (de) 1971-09-01 1973-03-08 Hoechst Ag 3,4-dihydro-2h-isochinolin-1-thione und verfahren zu ihrer herstellung
US3813384A (en) * 1972-01-17 1974-05-28 Asta Werke Ag Chem Fab Basically substituted benzyl phthalazone derivatives,acid salts thereof and process for the production thereof
FR2262513A1 (en) 1974-03-01 1975-09-26 Delalande Sa 3,4,5-Triphenyl-delta-1,2,4-oxadiazolines - with bronchodilator, anti-cholinergic, hypertensive, analgesic and sedative activity
JPS54156526A (en) 1978-05-31 1979-12-10 Asahi Chemical Ind Dry picture forming material
US4283539A (en) 1979-12-18 1981-08-11 Pfizer Inc. Isoquinoline acetic acids
JPS58164577A (ja) 1982-03-24 1983-09-29 Taiho Yakuhin Kogyo Kk ４―ベンジル―１―（２ｈ）イソキノロン誘導体
US4665181A (en) * 1984-05-17 1987-05-12 Pennwalt Corporation Anti-inflammatory phthalazinones
US5215738A (en) * 1985-05-03 1993-06-01 Sri International Benzamide and nicotinamide radiosensitizers
US5041653A (en) * 1985-05-03 1991-08-20 Sri International Substituted benzamide radiosensitizers
US5032617A (en) * 1985-05-03 1991-07-16 Sri International Substituted benzamide radiosensitizers
DE3677322D1 (de) * 1985-11-11 1991-03-07 Asta Pharma Ag 4-benzyl-1-(2h)-phthalazinon-derivate.
DE3612211A1 (de) * 1986-04-11 1987-10-15 Basf Ag Kontinuierliches verfahren zum tablettieren
DE3612212A1 (de) * 1986-04-11 1987-10-15 Basf Ag Verfahren zur herstellung von festen pharmazeutischen formen
GB8610018D0 (en) 1986-04-24 1986-05-29 Fujisawa Pharmaceutical Co Phthalazine derivatives
DE3640641A1 (de) * 1986-11-28 1988-07-14 Thomae Gmbh Dr K Neue heteroaromatische aminderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
ZA882639B (en) 1987-05-02 1988-09-30 Asta-Pharma Aktiengesellschaft New 2-aminoalkyl-4-benzyl-1(2h)-phthalazinone derivatives
DE3812567A1 (de) * 1988-04-15 1989-10-26 Basf Ag Verfahren zur herstellung pharmazeutischer mischungen
CA1334969C (en) 1988-08-19 1995-03-28 Mark James Suto Substituted dihydroisoquinoline and phthalazine derivatives as potentiators of the lethal effects of radiation and certain chemotherapeutic agents, selected compounds, analogs andprocess
EP0389995B1 (en) 1989-03-28 1995-05-31 Nisshin Flour Milling Co., Ltd. Isoquinoline derivatives for the treatment of glaucoma or ocular hypertension
DD287032A5 (de) 1989-07-28 1991-02-14 Karl-Marx-Universitaet Leipzig,De Verfahren zur herstellung von 3-carbamoyl-4-aryl-1,2-di-hydro-isochinolin-1h-onen
GB9011833D0 (en) 1990-05-25 1990-07-18 Collins Mary K L Inhibition of viral infection
MX9200299A (es) * 1991-02-07 1992-12-01 Roussel Uclaf Nuevos derivados biciclicos nitrogenados, su procedimiento de preparacion los nuevos compuestos intermedios obtenidos su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen.
US6004979A (en) * 1991-02-07 1999-12-21 Hoechst Marion Roussel Nitrogenous bicycles
EP0502575A1 (en) 1991-03-06 1992-09-09 Merck & Co. Inc. Substituted 1-(2H)-isoquinolinones
WO1993014086A1 (en) 1992-01-17 1993-07-22 Syntex (U.S.A.) Inc. Substituted 1-isoquinolone derivatives as angiotensin ii antagonists
CZ199593A3 (en) * 1992-10-02 1994-04-13 Asta Medica Ag Phthalazinone derivatives exhibiting anti-arrhythmic and analgesic activity and eliminating resistance to a plurality of medicaments (mdr)
AU5455194A (en) 1992-11-02 1994-05-24 Merck & Co., Inc. Substituted phthalazinones as nerotensin antagonists
EP0634404A1 (en) 1993-07-13 1995-01-18 Rhone Poulenc Agriculture Ltd. Phtalazin derivatives and their use as pesticides
US5587384A (en) * 1994-02-04 1996-12-24 The Johns Hopkins University Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity
US5648355A (en) * 1994-02-09 1997-07-15 Kos Pharmaceutical, Inc. Method of treatment of endogenous, painful gastrointestinal conditions of non-inflammatory, non-ulcerative origin
GB9404485D0 (en) 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
DK0699754T3 (da) 1994-08-12 2001-02-26 Myriad Genetics Inc Fremgangsmåde til diagnosticering af prædisposition for bryst- og ovariecancer
EP0705903B2 (en) 1994-08-12 2009-08-12 The University of Utah Research Foundation Mutations in the 17q-linked breast and ovarian cancer susceptibility gene
US5589483A (en) * 1994-12-21 1996-12-31 Geron Corporation Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence
US5834466A (en) 1994-12-22 1998-11-10 The Regents Of The University Of California Method for protecting of heart by limiting metabolic and ionic abnormalities developed during ischemia, following ischemia or resulting from ischemia
EP0721286A3 (en) 1995-01-09 2000-07-26 Matsushita Electric Industrial Co., Ltd. Video signal decoding apparatus with artifact reduction
MX9707561A (es) 1995-04-07 1997-12-31 Schering Corp Compuestos de carbonil piperazinilo y piperidinilo.
IL120264A0 (en) 1996-02-29 1997-06-10 Pfizer Method of reducing tissue damage associated with non-cardiac ischemia
US5854265A (en) * 1996-04-03 1998-12-29 Merck & Co., Inc. Biheteroaryl inhibitors of farnesyl-protein transferase
US6080870A (en) * 1996-04-03 2000-06-27 Merck & Co., Inc. Biaryl substituted imidazole compounds useful as farnesyl-protein transferase inhibitors
US5880140A (en) * 1996-04-03 1999-03-09 Merck & Co., Inc. Biheteroaryl inhibitors of farnesyl-protein transferase
US5872136A (en) * 1996-04-03 1999-02-16 Merck & Co., Inc. Arylheteroaryl inhibitors of farnesyl-protein transferase
US5883105A (en) * 1996-04-03 1999-03-16 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5939557A (en) * 1996-04-03 1999-08-17 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
CA2250232A1 (en) 1996-04-03 1997-10-09 Allen I. Oliff A method of treating cancer
US5874452A (en) * 1996-04-03 1999-02-23 Merck & Co., Inc. Biheteroaryl inhibitors of farnesyl-protein transferase
US5859035A (en) * 1996-04-03 1999-01-12 Merck & Co., Inc. Arylheteroaryl inhibitors of farnesyl-protein transferase
US6063930A (en) * 1996-04-03 2000-05-16 Merck & Co., Inc. Substituted imidazole compounds useful as farnesyl-protein transferase inhibitors
EP0952842A2 (en) 1996-04-18 1999-11-03 Merck & Co., Inc. A method of treating cancer
US5880128A (en) * 1996-05-08 1999-03-09 Schering Corporation Carbonyl piperazinyl and piperidinyl compounds
JP2000508335A (ja) 1996-05-30 2000-07-04 メルク エンド カンパニー インコーポレーテッド 癌の治療方法
CA2205757C (en) * 1996-05-30 2006-01-24 F. Hoffmann-La Roche Ag Pyridazinone derivatives and their use as inhibitors of prostaglandin g/h synthase i and ii(cox i and ii)
WO1997049384A1 (en) * 1996-06-26 1997-12-31 Board Of Regents, The University Of Texas System Hot-melt extrudable pharmaceutical formulation
DE19629753A1 (de) * 1996-07-23 1998-01-29 Basf Ag Verfahren zur Herstellung von festen Arzneiformen
US5854264A (en) * 1996-07-24 1998-12-29 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5888529A (en) 1997-03-28 1999-03-30 The Regents Of The University Of California Ileus treatment method
AU745790B2 (en) 1997-05-13 2002-03-28 Octamer, Inc. Methods for treating inflammation and inflammatory diseases using pADPRT inhibitors
US6060038A (en) * 1997-05-15 2000-05-09 Merck & Co., Inc. Radiolabeled farnesyl-protein transferase inhibitors
AU8784698A (en) 1997-08-15 1999-03-08 Johns Hopkins University, The Method of using selective parp inhibitors to prevent or treat neurotoxicity
US6635642B1 (en) 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
US20020022636A1 (en) 1997-09-03 2002-02-21 Jia-He Li Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity
US6291425B1 (en) 1999-09-01 2001-09-18 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage
US6197785B1 (en) * 1997-09-03 2001-03-06 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
US6426415B1 (en) * 1997-09-03 2002-07-30 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods and compositions for inhibiting parp activity
US6514983B1 (en) 1997-09-03 2003-02-04 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
WO1999025340A1 (en) * 1997-11-14 1999-05-27 Eli Lilly And Company Treatment for alzheimer's disease
JP2002505288A (ja) 1998-03-02 2002-02-19 コセンシス，インコーポレイテッド 置換キナゾリンおよびアナログならびにそれらの使用
FR2776291B1 (fr) 1998-03-18 2000-06-16 Pf Medicament Nouveaux derives bis-benzamides, leur procede de fabrication, les compositions pharmaceutiques les contenant et leur utilisation comme medicament
US6943168B2 (en) * 1998-06-30 2005-09-13 Neuromed Technologies Inc. Calcium channel inhibitors comprising benzhydril spaced from piperazine
US20040259866A1 (en) * 1998-06-30 2004-12-23 Snutch Terrance P. Calcium channel blockers comprising two benzhydril moieties
US6011035A (en) * 1998-06-30 2000-01-04 Neuromed Technologies Inc. Calcium channel blockers
US20040266784A1 (en) * 1998-06-30 2004-12-30 Snutch Terrance P. Calcium channel inhibitors comprising benzhydril spaced from piperazine
US6492375B2 (en) * 1998-06-30 2002-12-10 Neuromed Technologies, Inc. Partially saturated calcium channel blockers
US6951862B2 (en) * 1998-06-30 2005-10-04 Neuromed Technologies, Inc. Calcium channel blockers comprising two benzhydril moieties
US20060084660A1 (en) * 1998-06-30 2006-04-20 Neuromed Technologies Inc. Calcium channel blockers comprising two benzhydril moieties
US7186726B2 (en) * 1998-06-30 2007-03-06 Neuromed Pharmaceuticals Ltd. Preferentially substituted calcium channel blockers
US6387897B1 (en) * 1998-06-30 2002-05-14 Neuromed Technologies, Inc. Preferentially substituted calcium channel blockers
US6310059B1 (en) * 1998-06-30 2001-10-30 Neuromed Technologies, Inc. Fused ring calcium channel blockers
ITMI981671A1 (it) 1998-07-21 2000-01-21 Zambon Spa Derivati ftalazinici inibitori della fosfodisterasi 4
OA11749A (en) 1999-01-11 2005-07-19 Agouron Pharma Tricyclic inhibitors of poly(adp-ribose)polymerases.
US6677333B1 (en) * 1999-01-26 2004-01-13 Ono Pharmaceutical Co., Ltd. 2H-phthalazin-1-one derivatives and drug containing its derivatives as active ingredient
DE19921567A1 (de) * 1999-05-11 2000-11-16 Basf Ag Verwendung von Phthalazine-Derivaten
US6465467B1 (en) * 1999-05-21 2002-10-15 Biovitrum Ab Certain aryl-aliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases
CA2381401A1 (en) 1999-08-11 2001-02-15 Bristol-Myers Squibb Company Process for the preparation of a paclitaxel c-4 methyl carbonate analog
US6465448B1 (en) 1999-08-13 2002-10-15 Case Western Reserve University Methoxyamine potentiation of temozolomide anti-cancer activity
ECSP003637A (es) 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas
WO2001021615A1 (fr) 1999-09-17 2001-03-29 Yamanouchi Pharmaceutical Co., Ltd. Dérivés de benzimidazole
KR20010087401A (ko) 1999-09-28 2001-09-15 스타르크, 카르크 아제피노인돌 유도체, 그의 제법 및 용도
US6552016B1 (en) * 1999-10-14 2003-04-22 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
US6476048B1 (en) * 1999-12-07 2002-11-05 Inotek Pharamaceuticals Corporation Substituted phenanthridinones and methods of use thereof
DE19963607B4 (de) * 1999-12-23 2005-12-15 Schering Ag Verfahren zur Herstellung von 4-(Heteroaryl-methyl) halogen-1(2H)-phthalazinonen
WO2001057038A1 (de) * 2000-02-01 2001-08-09 Basf Aktiengesellschaft Heterozyklische verbindungen und deren anwendung als parp-inhibitoren
JPWO2001079184A1 (ja) 2000-04-18 2004-03-18 住友製薬株式会社 置換ピペラジン類
US7122679B2 (en) 2000-05-09 2006-10-17 Cephalon, Inc. Multicyclic compounds and the use thereof
DE10022925A1 (de) * 2000-05-11 2001-11-15 Basf Ag Substituierte Indole als PARP-Inhibitoren
WO2001087845A2 (en) 2000-05-15 2001-11-22 Fujisawa Pharmaceutical Co., Ltd. N-containing heterocyclic compounds and their use as 5-ht antagonists
US6723733B2 (en) 2000-05-19 2004-04-20 Guilford Pharmaceuticals, Inc. Sulfonamide and carbamide derivatives of 6(5H)phenanthridinones and their uses
US7498304B2 (en) * 2000-06-16 2009-03-03 Curis, Inc. Angiogenesis-modulating compositions and uses
AU2001275495B2 (en) * 2000-06-16 2006-08-17 Curis, Inc. Angiogenesis-modulating compositions and uses
PL223343B1 (pl) 2000-10-30 2016-10-31 Kudos Pharm Ltd Zastosowanie związku, kompozycja farmaceutyczna zawierająca związek oraz pochodne ftalazynonowe
AU2002226098A1 (en) * 2000-10-30 2002-05-15 The Board Of Regents, The University Of Texas System Spherical particles produced by a hot-melt extrusion/spheronization process
US7151102B2 (en) * 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
AU2002220241A1 (en) 2000-12-01 2002-06-11 Iconix Pharmaceuticals, Inc. Parb inhibitors
EP1217000A1 (en) * 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
GB0104752D0 (en) * 2001-02-27 2001-04-18 Astrazeneca Ab Pharmaceutical compositions
JPWO2002068407A1 (ja) 2001-02-28 2004-06-24 山之内製薬株式会社 ベンゾイミダゾール化合物
DE60218458T2 (de) 2001-05-08 2007-11-15 Kudos Pharmaceuticals Ltd. Isochinolinon derivate als parp inhibitoren
JPWO2002094790A1 (ja) * 2001-05-23 2004-09-09 三菱ウェルファーマ株式会社 縮合ヘテロ環化合物およびその医薬用途
WO2003007959A1 (en) 2001-07-16 2003-01-30 Fujisawa Pharmaceutical Co., Ltd. Quinoxaline derivatives which have parp inhibitory action
US20030073692A1 (en) * 2001-08-07 2003-04-17 Pharmacia & Upjohn S.P.A. Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
WO2003051879A1 (en) 2001-12-14 2003-06-26 Altana Pharma Ag Known and novel 4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-ones useful as poly(adp-ribose)polymerase inhibitors
AUPR975601A0 (en) 2001-12-24 2002-01-31 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivatives
IL162666A0 (en) * 2001-12-28 2005-11-20 Teva Pharma A stable pharmaceutical formulation of paroxetine hydrochloride and a process for preparation thereof
WO2003057145A2 (en) 2001-12-31 2003-07-17 Guilford Pharmaceuticals Inc. SUBSTITUTED 4,9-DIHYDROCYCLOPENTA[imn]PHENANTHRIDINE-5-ONES DERIVATIVES THEREOF AND THEIR USES
AUPS019702A0 (en) 2002-01-29 2002-02-21 Fujisawa Pharmaceutical Co., Ltd. Condensed heterocyclic compounds
RU2292337C2 (ru) * 2002-02-19 2007-01-27 Оно Фармасьютикал Ко., Лтд. Конденсированные производные пиридазина и лекарственные препараты, содержащие данные соединения в качестве активного ингредиента
EP2174939A1 (en) 2002-02-25 2010-04-14 Kudos Pharmaceuticals Limited Pyranones useful as ATM inhibitors
US20030195192A1 (en) * 2002-04-05 2003-10-16 Fortuna Haviv Nicotinamides having antiangiogenic activity
AUPS137402A0 (en) 2002-03-26 2002-05-09 Fujisawa Pharmaceutical Co., Ltd. Novel tricyclic compounds
US20040014744A1 (en) * 2002-04-05 2004-01-22 Fortuna Haviv Substituted pyridines having antiangiogenic activity
DE60335359D1 (de) * 2002-04-30 2011-01-27 Kudos Pharm Ltd Phthalazinonderivate
BRPI0408284B8 (pt) 2003-03-12 2021-05-25 Kudos Pharm Ltd compostos derivados de ftalazinona, seu uso e composição farmacêutica compreendendo os mesmos
US7449464B2 (en) * 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
EP1624859A4 (en) * 2003-05-06 2010-06-23 Bpsi Holdings Inc METHOD FOR PRODUCING THERMOFORMED COMPOSITIONS WITH ACRYLIC POLYMER BINDERS, PHARMACEUTICAL DOSAGE FORMS, AND METHOD FOR THE PRODUCTION THEREOF
US20050048112A1 (en) * 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form
US8025899B2 (en) † 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
KR20060123403A (ko) * 2003-12-01 2006-12-01 쿠도스 파마슈티칼스 리미티드 암 치료를 위한 ｄｎａ 손상 수복 억제제
CA2559285A1 (en) * 2004-03-18 2005-09-29 Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
US20050227999A1 (en) * 2004-04-09 2005-10-13 Neuromed Technologies Inc. Diarylamine derivatives as calcium channel blockers
EP1760071A4 (en) 2004-06-23 2008-03-05 Ono Pharmaceutical Co COMPOUND WITH S1P RECEPTOR BINDING ABILITY AND USE THEREOF
GB0419072D0 (en) * 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
US9504658B2 (en) * 2004-11-09 2016-11-29 Board Of Regents, The University Of Texas System Stabilized HME composition with small drug particles
US7517870B2 (en) * 2004-12-03 2009-04-14 Fondazione Telethon Use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization
DE102005011822A1 (de) * 2005-03-15 2006-09-21 Merck Patent Gmbh Phthalazinone
GB0521373D0 (en) * 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
PE20080422A1 (es) * 2006-08-10 2008-04-28 Cipla Ltd Composicion solida antirretroviral de administracion oral
UY30639A1 (es) * 2006-10-17 2008-05-31 Kudos Pharm Ltd Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
WO2008081829A1 (ja) * 2006-12-27 2008-07-10 Astellas Pharma Inc. 難水溶性薬物の溶解性維持用アミノアルキルメタアクリレートコポリマーｅ
DK2120579T3 (da) 2006-12-28 2014-02-03 Abbvie Inc Inhibitorer af poly(ADP-ripose)polymerase
EP1958615A1 (en) * 2007-02-13 2008-08-20 Bayer Schering Pharma Aktiengesellschaft Solid pharmaceutical formulations of a homogeneous dispersion of active principles having pH-dependent solubility
TW200900396A (en) * 2007-04-10 2009-01-01 Kudos Pharm Ltd Phthalazinone derivatives
ES2598178T5 (es) 2008-10-07 2023-12-26 Kudos Pharm Ltd Formulación farmacéutica 514

Also Published As

Publication number Publication date
US20200323847A1 (en) 2020-10-15
BR122021018683B1 (pt) 2022-11-16
WO2010041051A1 (en) 2010-04-15
US20230346780A1 (en) 2023-11-02
CU20110080A7 (es) 2011-12-28
CO6361906A2 (es) 2012-01-20
EP2346495A1 (en) 2011-07-27
CR20110186A (es) 2011-08-09
HN2011000947A (es) 2014-02-17
SI2346495T1 (sl) 2016-10-28
ZA201103333B (en) 2012-01-25
US20160008473A1 (en) 2016-01-14
ECSP11010960A (es) 2011-05-31
NI201100070A (es) 2012-03-19
CY2018030I2 (el) 2019-11-27
RS55157B1 (sr) 2017-01-31
SA109300599B1 (ar) 2014-02-17
NZ592719A (en) 2012-09-28
FI2346495T4 (fi) 2023-08-31
HUE030800T2 (en) 2017-05-29
LTPA2018014I1 (lt) 2018-12-10
US11633396B2 (en) 2023-04-25
CY1118190T1 (el) 2017-06-28
US20180133216A1 (en) 2018-05-17
HK1158528A1 (zh) 2012-07-20
SI2346495T2 (sl) 2023-10-30
CA2737400A1 (en) 2010-04-15
HRP20161154T1 (hr) 2016-11-18
KR101668499B1 (ko) 2016-10-21
US20140066447A1 (en) 2014-03-06
EP2346495B1 (en) 2016-07-20
BRPI0920604B1 (pt) 2021-11-23
CA2737400C (en) 2016-11-22
DK2346495T3 (en) 2016-09-26
US8475842B2 (en) 2013-07-02
US20230338372A1 (en) 2023-10-26
TW201018671A (en) 2010-05-16
JP5524220B2 (ja) 2014-06-18
US20230000862A1 (en) 2023-01-05
US20240382479A1 (en) 2024-11-21
DK2346495T4 (da) 2023-08-28
IL211809A (en) 2014-12-31
CY2018030I1 (el) 2019-11-27
HRP20161154T4 (hr) 2023-09-29
EP2346495B2 (en) 2023-05-24
PL2346495T5 (pl) 2024-06-10
DOP2011000094A (es) 2011-07-15
CN102238945A (zh) 2011-11-09
US12178816B2 (en) 2024-12-31
AR073792A1 (es) 2010-12-01
US12048695B2 (en) 2024-07-30
TWI461418B (zh) 2014-11-21
EA020783B1 (ru) 2015-01-30
CU24032B1 (es) 2014-10-02
AU2009300866B2 (en) 2013-03-28
UA106878C2 (uk) 2014-10-27
US20170173010A1 (en) 2017-06-22
AU2009300866A1 (en) 2010-04-15
IL211809A0 (en) 2011-06-30
US20190365751A1 (en) 2019-12-05
JP2012505158A (ja) 2012-03-01
ES2598178T3 (es) 2017-01-25
US20220249474A1 (en) 2022-08-11
US11975001B2 (en) 2024-05-07
CN102238945B (zh) 2014-10-29
MX2011003740A (es) 2011-05-02
UY32162A (es) 2010-05-31
ES2598178T5 (es) 2023-12-26
RS55157B2 (sr) 2023-10-31
NO2018038I1 (no) 2018-11-07
US20240398796A1 (en) 2024-12-05
BRPI0920604A2 (pt) 2020-09-15
CL2011000774A1 (es) 2011-08-05
PT2346495T (pt) 2016-11-11
EA201100595A1 (ru) 2011-12-30
PE20110893A1 (es) 2012-01-18
US12144810B1 (en) 2024-11-19
LT2346495T (lt) 2016-10-10
PL2346495T3 (pl) 2017-02-28
MY160340A (en) 2017-02-28
AR116035A2 (es) 2021-03-25
US20100098763A1 (en) 2010-04-22
KR20110066942A (ko) 2011-06-17
HUS1800043I1 (hu) 2018-11-28

Similar Documents

Publication Publication Date Title
ME02640B (me) Farmaceutske formulacije 514
JP5936705B2 (ja) 高融点疎水性化合物のバイオアベイラビリティが向上した薬学的組成物
KR100962447B1 (ko) 난용성 약물인 두타스테라이드의 자가유화 조성물과 이로부터 제조된 정제
AU2014225449B2 (en) Stabilization of moisture-sensitive drugs
EP3110406B1 (en) Pharmaceutical composition
CN108201537A (zh) 一种尼拉帕尼缓控释药物组合物及其用途
US20100136119A1 (en) Controlled-release preparation containing cilostazol and process for the preparation thereof
EA031395B1 (ru) Состав с модифицированной кинетикой высвобождения
KR20190048867A (ko) 수용해도 및 생체이용율이 개선된 소라페닙 나노입자 경구용 조성물 및 이의 제조 방법
WO2009013237A2 (en) Stable solid pharmaceutical composition comprising candesartan or pharmaceutically acceptable forms thereof
CA2833115C (en) Pharmaceutical compositions of raltegravir, methods of preparation and use thereof
EP2364694B1 (en) Controlled-release formulations of pramipexole
TWI722988B (zh) 緩釋性醫藥組合物及其製備方法
WO2003011256A1 (en) Oral controlled release pharmaceutical composition of a prokinetic agent
CN105560200A (zh) 难溶性药物控释片及其制备方法
WO2024184927A1 (en) Solid oral composition of olaparib and its salts thereof
WO2025151876A1 (en) Triptolide formulations
CA3232832A1 (en) Pharmaceutical composition and a process to prepare the same
CN104337783A (zh) 一种卡培他滨片剂及其制备方法
WO2025212071A1 (en) A solid dispersion of enzalutamide
KR20230088399A (ko) 듀테트라베나진을 포함하는 위체류성 제형
CN103169692B (zh) 一种决奈达隆药物组合物
WO2018093289A1 (ru) Пероральная твердая лекарственная форма и способ ее получения